Business & regional news

Stedi Extra Support Guidewire Delivers Enhanced Support for Stability, Safety, and Predictability During Valve Deployment for Aortic Stenosis

Partnership launches AI solution to enhance predictive heart valve visualization and personalize valve treatment planning decisions enabling the future of TAVR for structural heart patients

With this labeling approval, Medtronic continues to lead the way in advancing aortic care with clinical evidence for the treatment of ruptured abdominal aortic aneurysms (rAAA). Medtronic plc, a...

Indication demonstrates Medtronic’s commitment to innovative patient-centered solutions shaping the future of TAVR

The Medtronic TAVI indication builds upon commitment to provide best in class patient outcomes today and enabling lifetime management solutions for the future

Harmony™ Transcatheter Pulmonary Valve system approval expands minimally invasive treatment options for patients with congenital heart disease across European Union

Two data releases at London Valves 2024 build on Evolut’s legacy of valve design and performance: Optimize PRO study demonstrates improved procedure efficiencies and valve performance Pooled...

Collaboration with health technology company Tempus seeks to identify causes for undertreatment of minority patients with heart valve disease who may benefit from minimally invasive therapies

Newest-generation Evolut TAVI system builds on its market leading valve performance and durability with enhanced coronary access

New York Valves 2024: Late-breaking data included a SMART Trial secondary analysis showing significantly less bioprosthetic valve dysfunction with Evolut TAV across the entire range of small annulus areas when compared with the Edwards Sapien 3™ TAV platform, and CoreValve-Evolut pooled analysis demonstrating valve performance and durability benefits versus surgery.

Medtronic, the global leader in healthcare technology, today announced the release of important clinical outcomes in two leading transcatheter valve therapies. The results for these studies were...

CRT 2024: Evolut TAVR is a safe, effective, and economically cost-effective treatment option for low-risk severe aortic stenosis patients compared to surgery up to four years

Next-Gen Evolut FX TAVI system enhances procedure ease-of-use, visualization, and predictability

40-site pilot program across US, UK, and Europe aims to introduce cutting edge AI solutions into the clinical environment to improve patient care and efficiency

SCAI 2023 Scientific Sessions: Harmony™ Transcatheter Pulmonary Valve System Demonstrates Strong Clinical and Hemodynamic Outcomes at Two Years

Presented at Charing Cross, 10-Year Clinical Data from Global ENGAGE OUS Registry Support Endurant Stent Graft System’s AAA Market-Leading Position Worldwide

ACC.23/WCC Late-Breaking Clinical Trial: Evolut™ is only TAVR to show excellent outcomes in low-risk patients at 3 years

CRT 2023 Late-Breaking Data: CoreValve/Evolut™ platform demonstrates significantly lower bioprosthetic valve dysfunction compared to surgery at five years

Harmony™ Transcatheter Pulmonary Valve System is the first FDA-approved minimally invasive valve designed for the right side of the heart

ADVANCE Trial compares sac regression in the Medtronic Endurant™ II/IIs stent graft system and the Gore® Excluder®* AAA Device Family systems

London Valves 2022: Latest Transcatheter Aortic Valve Replacement Data for Treatment of Aortic Stenosis and Prosthetic Aortic Valve Degeneration

Medtronic announced today that it recently received CE mark for its Radiant™ balloon-expandable covered stent, the first and currently only covered stent indicated for use in ChEVAR with the...

TCT 2022: Late-breaking data from Intrepid™ Pilot Study 3-year follow-up & 1-year follow-up from Transfemoral EFS study demonstrate promising valve performance Medtronic today announced new data...

TCT 2022: Pathological Findings Confirm Importance of Early Detection and Treatment of Thrombus on Valve Leaflets Medtronic today announced findings from its Pathological Study of Hypo-Attenuated...

TCT 2022: Medtronic Unveils Latest Transcatheter Aortic Valve Replacement Data in Late-Breaking Clinical Science and Presentations

Mid-term results of Optimize PRO clinical study reinforces benefits of predictability and control using cusp overlap technique

EXPAND TAVR II Pivotal Trial evaluating the Evolut™ TAVR platform in a new patient population

ACC.22: Late-breaking data show CoreValve™ and Evolut™ is the only platform to out-perform surgery in valve durability at five years